Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225647 | 0.95 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2POLBHTTUSP2 | |
| SCHEMBL24693047 | 0.91 | HPGD (0.56) | ALDH1A1SMN1; SMN2POLBHTTUSP2 | |
| SCHEMBL31117913 | 0.89 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2POLBHTTUSP2 | |
| SCHEMBL24693482 | 0.88 | SMN1; SMN2 (0.62) | ALDH1A1SMN1; SMN2POLBHTTUSP2 | |
| SCHEMBL7427536 | 0.86 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2POLBHTTUSP2 | |
| SCHEMBL18294 | 0.84 | USP2 (0.69) | ALDH1A1SMN1; SMN2POLBHTTUSP2 | |
| SCHEMBL698803 | 0.84 | USP2 (0.69) | ALDH1A1SMN1; SMN2POLBHTTUSP2 | |
| SCHEMBL23144532 | 0.84 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2POLBHTTUSP2 | |
| SCHEMBL8431612 | 0.83 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2POLBHTTUSP2 | |
| SCHEMBL1970198 | 0.83 | USP2 (0.55) | ALDH1A1SMN1; SMN2USP2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252953-A1 | Targeting Human Thymidylate Kinase Induces DNA Repair Toxicity in Malignant Tumor Cells | NATIONAL YANG-MING UNIVERSITY (TW) | 2013-09-26 | — | — | US | claimed |
| CN-118108709-B | Preparation method and application of target CDK19 radionuclide labeling reagent | 中国医学科学院放射医学研究所 | 2026-05-19 | — | — | CN | disclosed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4355741-B1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250368608-A1 | SELECTIVE HDAC6 INHIBITOR | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2025-12-04 | — | — | US | disclosed |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-1999016751-A1 | BENZAMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999011612-A2 | SUBSTITUTED CYCLIC COMPOUNDS AND MIXTURES COMPRISING SAME | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| US-5880284-A | HAVING ANTITHROMBOTIC, ANTIAGGREGATORY AND TUMOR- OR METASTASES-INHIBITING EFFECTS | DR. KARL THOMAE GMBH (DE) | 1999-03-09 | — | — | US | disclosed |
| EP-0861249-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5753660-A | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1998005961-A1 | COMPOUNDS HAVING A PLURALITY OF NITROGENOUS SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| US-5681841-A | PREVENTION CELL AGGREGATION | KARL THOMAE GMBH (DE) | 1997-10-28 | — | — | US | disclosed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | disclosed |
| WO-1997014685-A1 | PYRIMIDINE DERIVATIVES | GYÓGYSZERKUTATÓ INTÉZET KFT (HU) | 1997-04-24 | — | — | WO | disclosed |
| EP-0587134-A2 | Cyclic urea derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368608-A1 | SELECTIVE HDAC6 INHIBITOR | HDAC6, HDAC3, HDAC1 | ALDH1A1 3394/4885SMN1; SMN2 671/4885POLB 3475/4885 |
| US-20130252953-A1 | Targeting Human Thymidylate Kinase Induces DNA Repair Toxicity in Malignant Tumor Cells | DTYMK, TYMP, DCK | ALDH1A1 1837/4885SMN1; SMN2 4078/4885POLB 89/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | ALDH1A1 3824/4885SMN1; SMN2 2586/4885POLB 3/4885 |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | ALDH1A1 2230/4885SMN1; SMN2 716/4885POLB 22/4885 |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | ALDH1A1 774/4885SMN1; SMN2 2951/4885POLB 1734/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | ALDH1A1 3824/4885SMN1; SMN2 2586/4885POLB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.